Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      
side 1 / 251
Opret nyt indlæg

Ambu vs. Munters Group - Hvad er forskellen
14/6 09:37 Hans-Henrik Nielsen Svar: 0

FED skaber rod i markedet
12/6 21:37 Hans-Henrik Nielsen Svar: 0

NOVO´s Semaglutide med flotte data fase 3
9/6 15:05 Helge Larsen/PI-redaktør Svar: 0

Vi kigger på toldkrig med Mexico, renteudme..
9/6 12:09 Hans-Henrik Nielsen Svar: 0

Et TA-aktiekig i et volatilt marked
4/6 19:38 Hans-Henrik Nielsen Svar: 0

Så har jeg købt guld til min TA-portefølje
3/6 10:51 Hans-Henrik Nielsen Svar: 4

Kina spiller et vigtigt kort i handelskrigen
29/5 12:12 Hans-Henrik Nielsen Svar: 0

Axel Steuchs "Vinderstrategier i aktiemarke..
28/5 10:24 TeamGarlic Svar: 0

Vi kigger på stærke op- og nedtrends i mark..
26/5 15:29 Hans-Henrik Nielsen Svar: 1

Hvornår skal man købe i en stærk optrend?
22/5 11:20 Hans-Henrik Nielsen Svar: 1

Vi tager et TA-kig på laks og Rockwool
20/5 11:22 Hans-Henrik Nielsen Svar: 1

TA-porteføljen indtil nu i år: +12,99%
17/5 11:20 Hans-Henrik Nielsen Svar: 1

Anbefaling af bog - Gud bevare afdragsfrihe..
16/5 09:12 TeamGarlic Svar: 4

En fantastisk dag for Fingerprint
15/5 22:50 Hans-Henrik Nielsen Svar: 0

Transcript - Q&A Genmab Q1 2019
14/5 14:02 Helge Larsen/PI-redaktør Svar: 0

Ambu
14/5 13:43 internetulv Svar: 1

Aktiefald i et nervøst marked - Hvad siger ..
13/5 11:12 Hans-Henrik Nielsen Svar: 0

Et svært marked at kloge sig på
10/5 10:26 Hans-Henrik Nielsen Svar: 1

Genmab Q1 - Darzalex Guidance m.m
10/5 00:52 Sukkeralf Svar: 1

Spændende aktier i et spændende marked
8/5 11:53 Hans-Henrik Nielsen Svar: 0

En analyse af handelskrigen på kort, mellem..
6/5 10:34 Hans-Henrik Nielsen Svar: 0

FA data på OMXC25, OMXS30, OMXH25, OMXO20
5/5 11:08 Landsknecht Svar: 1

Et kig på markedet med let bekymring
3/5 09:12 Hans-Henrik Nielsen Svar: 1

Spændende danske TA-kandidater på 1. maj
1/5 11:23 Hans-Henrik Nielsen Svar: 1

Denne gang er det helt anderledes! Eller er..
29/4 10:13 Hans-Henrik Nielsen Svar: 2

Spændende skandinaviske TA-kandidater
28/4 15:40 Hans-Henrik Nielsen Svar: 0

Et TA-kig på Helges spændende kandidater
25/4 22:19 Hans-Henrik Nielsen Svar: 0

En spændende svensk kandidat på listen
22/4 11:27 Hans-Henrik Nielsen Svar: 1

Tradingview - Indikatorer og smarte værktøj..
19/4 13:18 Hans-Henrik Nielsen Svar: 0

Genmab - New Duobody Trial
17/4 16:12 Helge Larsen/PI-redaktør Svar: 0

Darzalex salgstal Q1 2019
17/4 13:51 peter12 Svar: 1

Hvor skal Cbrain hen efter de store stignin..
16/4 22:05 Hans-Henrik Nielsen Svar: 0

Nordea opjusterer kursmål på Scatec Solar
15/4 12:07 Helge Larsen/PI-redaktør Svar: 0

LANGERS SKARPE: Højere renter største truss..
14/4 11:50 Helge Larsen/PI-redaktør Svar: 0

"De renfærdige. Fortællingen om Novo Nordis..
13/4 14:37 Helge Larsen/PI-redaktør Svar: 0

Vi tager et TA-kig på laksesektoren
13/4 14:09 Hans-Henrik Nielsen Svar: 0

Fantastisk og gratis aktieskanner
12/4 10:59 Hans-Henrik Nielsen Svar: 0

Video - Holberg Sjømatseminar mars 2019
12/4 10:16 Helge Larsen/PI-redaktør Svar: 0

Hvad siger TA om Veloxis, Teva og Fingerpri..
11/4 08:28 Hans-Henrik Nielsen Svar: 1

Video - Genmab Celebrating 20 Years
10/4 21:20 Helge Larsen/PI-redaktør Svar: 0

Skiftedag i TA-porteføljen - Hvad bliver de..
9/4 11:04 Hans-Henrik Nielsen Svar: 1

Lakseaktierne hænger bagefter totalindekset
9/4 07:39 Helge Larsen/PI-redaktør Svar: 0

Langers skarpe - Aktiemarkedet spiller på a..
8/4 12:47 Helge Larsen/PI-redaktør Svar: 0

Servicetjek af min TA-portefølje
8/4 11:32 Hans-Henrik Nielsen Svar: 0

Er big data ved at disrupte Pharma?
8/4 10:52 exitnu Svar: 0

Genmab/Barclays: Kursmål hæves til 1300 kr..
8/4 07:19 Helge Larsen/PI-redaktør Svar: 1

Data fra konkurren styrker troen på ASX-101..
6/4 08:24 Helge Larsen/PI-redaktør Svar: 0

Vi kigger på handelskrig, nøgletal og dansk..
5/4 09:40 Hans-Henrik Nielsen Svar: 0

Genmab
5/4 07:24 Doublo Svar: 1

Shortandelen på den norske børs er den lave..
4/4 22:21 Helge Larsen/PI-redaktør Svar: 0


NOVO´s Semaglutide med flotte data fase 3

  


08 Jun 2019 17:46 CET
Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza®

San Francisco, US, 8 June 2019 ­- Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza® (liraglutide 1.8 mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes. Data from both trials were presented at the American Diabetes Association (ADA) 79th Scientific Sessions. Oral semaglutide is an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue in a pill.

In PIONEER 2, oral semaglutide 14 mg demonstrated a superior HbA1c reduction of 1.3% compared to a 0.9% reduction with empagliflozin 25 mg for the primary endpoint at 26 weeks (p<0.0001) and a statistically significant reduction in HbA1c for the secondary endpoint at 52 weeks. Furthermore, for the secondary endpoint, the reduction in body weight with oral semaglutide was similar to empagliflozin with no statistical differences at both 26 and 52 weeks (3.8 kg for oral semaglutide at both 26 and 52 weeks, 3.7 kg and 3.6 kg for empagliflozin, respectively).

In PIONEER 4, for the primary endpoint at 26 weeks, oral semaglutide 14 mg demonstrated a non-inferior reduction in HbA1c vs Victoza® (1.2% vs 1.1%, respectively) and a superior reduction vs placebo (1.2% vs 0.2%, respectively) in adults with type 2 diabetes inadequately controlled on metformin, with or without a sodium-glucose co-transporter-2 (SGLT-2) inhibitor. For the secondary endpoint at 52 weeks, oral semaglutide demonstrated statistically significant reductions in HbA1c vs both Victoza® (1.2% vs 0.9%, respectively) and placebo (1.2% vs 0.2%, respectively). For the secondary endpoint of change in body weight, oral semaglutide demonstrated superior reductions compared to both Victoza® and placebo at 26 weeks (4.4 kg for oral semaglutide, 3.1 kg for Victoza® and 0.5 kg for placebo) and statistically significant reductions compared to both at 52 weeks (4.3 kg for oral semaglutide, 3.0 kg for Victoza®) and 1.0 kg for placebo).

In PIONEER 2, the most common adverse event for oral semaglutide was nausea, which diminished over time, affecting 20% of people treated with oral semaglutide. The nausea rate for empagliflozin was 2%. The proportion of people who discontinued treatment due to adverse events was 11% for those treated with oral semaglutide compared to 4% for those treated with empagliflozin.

In PIONEER 4, the most common adverse event for oral semaglutide was nausea, which diminished over time, affecting 20% of people treated with oral semaglutide. For people treated with Victoza® and placebo, 18% and 4%, respectively, experienced nausea. The proportion of people who discontinued treatment due to adverse events was 11% for those treated with oral semaglutide compared to 9% with Victoza® and 4% with placebo.

These results are based on the primary statistical approach known as the treatment policy (TPol) estimand, which was used to assess the effects of oral semaglutide regardless of discontinuation of trial product and/or use of rescue medication.

"Despite their proven safety and efficacy, GLP-1 receptor agonists are underutilized in clinical care" said Ildiko Lingvay, PIONEER 2 and 4 investigator and professor at the Departments of Internal Medicine and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas. "As a treating physician, I'm encouraged by these findings and the potential of investigational oral semaglutide to be the first oral GLP-1 receptor agonist available as a new treatment option for people living with type 2 diabetes."

The following results from PIONEER 2 and 4 were also presented today at the ADA and are based on the secondary statistical approach. The secondary statistical approach is known as the trial product estimand and is used to assess the effect of oral semaglutide, assuming all patients remained on trial product and did not use rescue medication:

PIONEER 2:

Oral semaglutide demonstrated statistically significant reductions in HbA1c vs empagliflozin at 26 weeks (1.4% vs 0.9%, respectively) and at 52 weeks (1.3% vs 0.8%, respectively).
Oral semaglutide demonstrated a body weight reduction of 4.2 kg vs 3.8 kg with empagliflozin at 26 weeks and a statistically significant reduction of 4.7 kg vs 3.8 kg at 52 weeks.

PIONEER 4:

Oral semaglutide demonstrated statistically significant reductions in HbA1c vs Victoza® and vs placebo at both 26 and 52 weeks (1.3% for oral semaglutide, 1.1% for Victoza® and 0.1% for placebo at 26 weeks; 1.2% for oral semaglutide, 0.9% for Victoza® and a 0.2% increase for placebo at 52 weeks).
Oral semaglutide demonstrated statistically significant reductions in body weight vs Victoza® and vs placebo at both 26 and 52 weeks (4.7 kg for oral semaglutide, 3.2 kg for Victoza® and 0.7 kg for placebo at 26 weeks; 5.0 kg for oral semaglutide, 3.1 kg for Victoza® and 1.2 kg for placebo at 52 weeks).

About PIONEER 2, PIONEER 4 and the PIONEER clinical trial programmePIONEER 2 was a 52-week, randomised, open-label, active-controlled, parallel-group, multicentre, multinational trial with two arms comparing the efficacy and safety of oral semaglutide 14 mg with empagliflozin 25 mg in people with type 2 diabetes, inadequately controlled on metformin. 822 people were enrolled in PIONEER 2 and randomised 1:1 to receive either oral semaglutide or empagliflozin once daily. The primary endpoint was change in HbA1c from baseline to week 26 and the confirmatory secondary endpoint was change in body weight from baseline to week 26. Additional key secondary endpoints included change in HbA1c and body weight from baseline to week 52.

PIONEER 4 was a 52-week, randomised, double-blinded, double-dummy, active- and placebo-controlled, parallel-group, multicentre, multinational trial with three arms comparing the efficacy and safety of oral semaglutide 14 mg compared to Victoza® (1.8 mg liraglutide) or placebo in people with type 2 diabetes, inadequately controlled on metformin with or without an SGLT-2 inhibitor. PIONEER 4 randomised 711 people in a 2:2:1 manner to receive either oral semaglutide, Victoza® or placebo once-daily. The primary endpoint was change from baseline to week 26 in HbA1c. Key secondary endpoints included change in HbA1c and body weight from baseline to week 52.

The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme that enrolled 9,543 people with type 2 diabetes across 10 clinical trials.

Further information
Media:
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com

Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

______________________ References

Montanya E, Rosenstock J, Canani LH, et al. Oral semaglutide vs empagliflozin added-on to metformin monotherapy in uncontrolled type 2 diabetes: PIONEER 2. Abstract number 54-OR, American Diabetes Association 79th Scientific Session, San Francisco, US; 7-11 June 2019
Pratley RE, Amod A, Hoff ST, et al. Oral Semaglutide vs Liraglutide and Placebo in T2D: PIONEER 4. Abstract number 55-OR, American Diabetes Association 79th Scientific Session, San Francisco, US; 7-11 June 2019

RSS feeds

Company announcement

News releases





side 1 / 251
Opret nyt indlæg